Back to News
Oct 22, 2025 4:00 PM

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.

NVS is trading near recent highs. Track the action here

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

Patients were randomized into three treatment arms: Cosentyx 300mg, Cosentyx 150mg, or placebo, all in combination with a 24-week steroid taper regimen.

Also Read: Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

Data

The trial's primary endpoint was whether secukinumab 300mg plus a 24-week steroid taper is superior to ...